Add BrightSurf on Google Email

Science News for September 11, 2022


Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Researchers found that starting pembrolizumab before surgery significantly improves the outlook for patients with stage III-IV melanoma. The study showed a 42% lower event rate in patients receiving neoadjuvant therapy compared to those receiving adjuvant therapy.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateSep 11, 2022
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.